

Antibody evasion by the P.1 strain of SARS-CoV-2

Cell

184, 2939-2954.e9

DOI: [10.1016/j.cell.2021.03.055](https://doi.org/10.1016/j.cell.2021.03.055)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. Computational and Structural Biotechnology Journal, 2021, 19, 3799-3809.	1.9	24
2	Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: An Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document. Clinical Infectious Diseases, 2022, 74, 1496-1502.	2.9	20
3	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerging Microbes and Infections, 2021, 10, 1097-1111.	3.0	25
4	Population Impact of SARS-CoV-2 Variants with Enhanced Transmissibility and/or Partial Immune Escape. SSRN Electronic Journal, 0, , .	0.4	0
11	BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2895-2998.	2.7	29
12	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science, 2021, 373, 818-823.	6.0	309
13	COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nature Medicine, 2021, 27, 1230-1238.	15.2	279
16	Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination. Open Forum Infectious Diseases, 2022, 9, .	0.4	38
18	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. Diagnostics, 2021, 11, 941.	1.3	45
25	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nature Communications, 2021, 12, 3815.	5.8	44
26	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Microorganisms, 2021, 9, 1389.	1.6	4
29	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. Viruses, 2021, 13, 1192.	1.5	150
32	Engineered single-domain antibodies tackle COVID variants. Nature, 2021, 595, 176-178.	13.7	8
35	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. Comptes Rendus - Biologies, 2021, 344, 77-110.	0.1	4
38	Tackling COVID-19 with neutralizing monoclonal antibodies. Cell, 2021, 184, 3086-3108.	13.5	309
39	FnCas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip. ELife, 2021, 10, .	2.8	53
40	SARS-CoV-2 Antiviral Therapy. Clinical Microbiology Reviews, 2021, 34, e0010921.	5.7	64
43	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. International Journal of Molecular Sciences, 2021, 22, 7425.	1.8	69

#	ARTICLE	IF	CITATIONS
46	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. <i>Current Medical Science</i> , 2021, 41, 1037-1051.	0.7	136
48	Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
49	Conformational Variability Correlation Prediction of Transmissibility and Neutralization Escape Ability for Multiple Mutation SARS-CoV-2 Strains using SSSCPreds. <i>ACS Omega</i> , 2021, 6, 19323-19329.	1.6	6
50	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
51	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
52	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. <i>Nature Medicine</i> , 2021, 27, 1744-1751.	15.2	148
57	Phytocompounds of <i>Rheum emodi</i> , <i>Thymus serpyllum</i> , and <i>Artemisia annua</i> Inhibit Spike Protein of SARS-CoV-2 Binding to ACE2 Receptor: In Silico Approach. <i>Current Pharmacology Reports</i> , 2021, 7, 135-149.	1.5	50
59	Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 224, 1278-1286.	1.9	77
60	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. <i>Cell Reports</i> , 2021, 36, 109433.	2.9	75
61	After the pandemic: perspectives on the future trajectory of COVID-19. <i>Nature</i> , 2021, 596, 495-504.	13.7	260
62	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88
63	Use of Monoclonal Antibody to Treat COVID-19 in Children and Adolescents: Risk of Abuse of Prescription and Exacerbation of Health Inequalities. <i>Pharmaceuticals</i> , 2021, 14, 673.	1.7	4
64	Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada. <i>Clinical Infectious Diseases</i> , 2022, 74, 1158-1165.	2.9	40
66	Early detection of the SARS-CoV-2 P.1 variant in Rio Grande do Sul, Brazil: a case report. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1997-1999.	1.0	5
67	Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. <i>ChemistrySelect</i> , 2021, 6, 7981-7998.	0.7	18
70	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
73	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. <i>ELife</i> , 2021, 10, .	2.8	267
74	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630

#	ARTICLE	IF	CITATIONS
75	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. <i>Pathogens</i> , 2021, 10, 1030.	1.2	33
76	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
77	Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein. <i>Infectious Diseases of Poverty</i> , 2021, 10, 112.	1.5	8
79	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	6.6	46
81	The rapid adaptation of SARS-CoV-2â€“rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
82	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. <i>Exploration of Immunology</i> , 2021, , 199-225.	1.7	5
83	An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. <i>Turkish Journal of Biology</i> , 2021, 45, 342-357.	2.1	3
84	The future of COVID-19: A vaccine review. <i>Journal of Infection and Public Health</i> , 2021, 14, 1461-1465.	1.9	16
85	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 135-140.	1.0	46
86	Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 722766.	2.2	20
87	SARS-CoV-2 Variants in Patients with Immunosuppression. <i>New England Journal of Medicine</i> , 2021, 385, 562-566.	13.9	333
88	Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 1841-1852.e4.	6.6	114
89	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab430.	0.4	18
90	The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein. <i>Virus Evolution</i> , 2021, 7, veab069.	2.2	31
92	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
94	Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. <i>Diagnostics</i> , 2021, 11, 1788.	1.3	8
95	The SARS-CoV-2 spike protein is vulnerable to moderate electric fields. <i>Nature Communications</i> , 2021, 12, 5407.	5.8	26
98	COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants. <i>Cell</i> , 2021, 184, 5077-5081.	13.5	114

#	ARTICLE	IF	CITATIONS
99	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	4.7	83
100	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 752003.	2.2	62
102	Vaccines for COVID-19: Where do we stand in 2021?. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 22-31.	1.2	53
103	Neutralizing antibodies for the prevention and treatment of COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2293-2306.	4.8	91
104	Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures. <i>Scientific Reports</i> , 2021, 11, 17755.	1.6	19
105	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
107	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
108	Chitosan derivatives: A suggestive evaluation for novel inhibitor discovery against wild type and variants of SARS-CoV-2 virus. <i>International Journal of Biological Macromolecules</i> , 2021, 187, 492-512.	3.6	17
110	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
111	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	16
112	Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. <i>The Lancet Regional Health Americas</i> , 2021, 1, 100025.	1.5	116
113	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
114	Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. <i>Nature Communications</i> , 2021, 12, 5730.	5.8	90
115	Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK. <i>Lancet Microbe</i> , The, 2021, 2, e416-e418.	3.4	16
116	Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2021, 17, e1009897.	2.1	49
118	Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. <i>Journal of Virology</i> , 2021, 95, e0143721.	1.5	24
119	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100171.	3.0	70
121	Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	61

#	ARTICLE	IF	CITATIONS
122	The Potential Beneficial Effects of Vaccination on Antigenically Evolving Pathogens. <i>American Naturalist</i> , 2022, 199, 223-237.	1.0	6
123	Pseudoephedrine and its derivatives antagonize wild and mutated severe acute respiratory syndrome (SARS-CoV-2) viruses through blocking virus invasion and anti-inflammatory effect. <i>Phytotherapy Research</i> , 2021, 35, 5847-5860.	2.8	8
124	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 690621.	1.8	60
126	The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants. <i>Cell Reports</i> , 2021, 36, 109679.	2.9	12
127	Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. <i>Journal of Infection</i> , 2021, 83, 467-472.	1.7	28
128	Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , 2021, 187, 106569.	1.3	28
129	Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. <i>Lancet Microbe</i> , The, 2021, 2, e527-e535.	3.4	92
130	The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. <i>Biochemical and Biophysical Research Communications</i> , 2021, 578, 91-96.	1.0	39
131	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in Naïve and COVID-19-Recovered Vaccine Recipients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
132	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 1390-1403.	3.0	16
134	Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
135	A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. <i>Vaccines</i> , 2021, 9, 1106.	2.1	5
136	Effectiveness of COVID-19 vaccines and their challenges (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1407.	0.8	23
137	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	2.9	36
138	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
139	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
140	Imidazoles and benzimidazoles as putative inhibitors of SARS-CoV-2 B.1.1.7 (Alpha) and P.1 (Gamma) variant spike glycoproteins: A computational approach. <i>Chemical Papers</i> , 2021, , 1-11.	1.0	4
141	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9

#	ARTICLE	IF	CITATIONS
142	Polyclonal F(abâ€™™)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency. <i>IScience</i> , 2021, 24, 103315.	1.9	23
143	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <i>Scientific Reports</i> , 2021, 11, 20274.	1.6	33
144	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
145	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	1.5	29
146	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. <i>Science Translational Medicine</i> , 2022, 14, eabj7521.	5.8	71
149	Altered O-glycomes of Renal Brush-Border Membrane in Model Rats with Chronic Kidney Diseases. <i>Biomolecules</i> , 2021, 11, 1560.	1.8	5
151	SARS-CoV-2 Virusâ€™Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10836.	1.8	25
152	Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 753249.	1.8	6
155	The impact of the <scp>SARSâ€™CoV</scp>â€™2 pandemic on the management of chronic limbâ€™threatening ischemia and wound care. <i>Wound Repair and Regeneration</i> , 2022, 30, 7-23.	1.5	4
156	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
157	SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101371.	1.6	6
158	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
159	Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document. <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0165921.	1.8	13
160	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
161	Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. <i>Antiviral Research</i> , 2021, 196, 105206.	1.9	1
162	Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations. <i>Scientific Reports</i> , 2021, 11, 21735.	1.6	11
164	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	4.6	6
165	Cluster of SARS-CoV-2 Gamma Variant Infections, Parintins, Brazil, March 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 262-264.	2.0	11

#	ARTICLE	IF	CITATIONS
166	The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. <i>ELife</i> , 2021, 10, .	2.8	24
167	COVID-19 vaccinations: The unknowns, challenges, and hopes. <i>Journal of Medical Virology</i> , 2022, 94, 1336-1349.	2.5	75
168	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe</i> , The, 2022, 3, e52-e61.	3.4	436
169	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
171	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
172	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
173	The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	4
175	Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2021, 29, 1788-1801.e6.	5.1	145
176	A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue. <i>Diagnostics</i> , 2021, 11, 2092.	1.3	6
178	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12.	5.1	52
180	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
181	SARS-CoV-2 Variants: Past, Present and Future. <i>Economics, Law, and Institutions in Asia Pacific</i> , 2022, , 3-23.	0.4	0
182	The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines. <i>Biochemical Society Transactions</i> , 2021, 49, 2879-2890.	1.6	16
183	Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105147.	1.0	13
184	SARS-CoV-2 introduction and lineage dynamics across three epidemic peaks in Southern Brazil: massive spread of P.1. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105144.	1.0	14
185	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
186	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	4.7	21
187	An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. <i>Nature Immunology</i> , 2022, 23, 50-61.	7.0	110

#	ARTICLE	IF	CITATIONS
190	SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody. <i>Computers in Biology and Medicine</i> , 2022, 142, 105226.	3.9	26
191	Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, e0150421.	1.2	17
192	Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. <i>Journal of Infection and Public Health</i> , 2022, 15, 156-163.	1.9	10
193	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	1.0	8
195	Mechanistic insights of CRISPR/Cas nucleases for programmable targeting and early-stage diagnosis: A review. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114033.	5.3	23
196	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. <i>Science Translational Medicine</i> , 2022, 14, eabl8124.	5.8	143
197	Looking at COVID-19 from a Systems Biology Perspective. <i>Biomolecules</i> , 2022, 12, 188.	1.8	1
198	A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 23.	7.1	11
199	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
200	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
202	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
203	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2022, 375, .	6.0	68
206	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
207	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
208	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
210	The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 78.	1.5	64
212	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
213	A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. <i>Science Translational Medicine</i> , 2022, 14, eabl7430.	5.8	241

#	ARTICLE	IF	CITATIONS
214	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	5.1	153
215	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. <i>BMC Molecular and Cell Biology</i> , 2022, 23, 2.	1.0	10
217	Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus. <i>Frontiers in Medicine</i> , 2021, 8, 793437.	1.2	4
218	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. <i>Npj Vaccines</i> , 2022, 7, 7.	2.9	35
219	Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. <i>Vaccine</i> , 2022, 40, 811-818.	1.7	9
221	Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada. <i>Journal of Infectious Diseases</i> , 2022, 226, 485-496.	1.9	8
222	Predicting the mutational drivers of future SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2022, 14, eabk3445.	5.8	101
223	Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article. <i>International Journal of Surgery</i> , 2022, 98, 106233.	1.1	21
224	CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant. <i>Viruses</i> , 2022, 14, 305.	1.5	2
225	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	5.9	78
226	In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105236.	1.0	6
227	In Silico Molecular Characterization of Human TMPRSS2 Protease Polymorphic Variants and Associated SARS-CoV-2 Susceptibility. <i>Life</i> , 2022, 12, 231.	1.1	5
228	Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, 811004.	1.2	3
229	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
230	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	20
231	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
232	In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 28.	0.9	12
233	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. <i>Cell Reports</i> , 2021, 37, 110156.	2.9	67

#	ARTICLE	IF	CITATIONS
234	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	13.7	249
238	Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). <i>Science Advances</i> , 2021, 7, eabk0172.	4.7	32
239	Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. <i>EMBO Reports</i> , 2022, 23, e53865.	2.0	18
240	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2021, , eabl6251.	6.0	12
241	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
242	Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
243	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
244	SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. <i>Science</i> , 2022, 375, 782-787.	6.0	60
245	In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron. <i>Viruses</i> , 2022, 14, 390.	1.5	7
246	Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. <i>Cell Discovery</i> , 2022, 8, 16.	3.1	18
247	Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections. <i>Frontiers in Immunology</i> , 2022, 13, 773652.	2.2	9
248	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. <i>Frontiers in Microbiology</i> , 2022, 13, 828806.	1.5	17
249	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. <i>Nature Communications</i> , 2022, 13, 871.	5.8	107
250	Genomic Surveillance of SARS-CoV-2 Lineages Indicates Early Circulation of P.1 (Gamma) Variant of Concern in Southern Brazil. <i>Microbiology Spectrum</i> , 2022, 10, e0151121.	1.2	8
251	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	2.1	81
252	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
254	Emergence of Two Distinct SARS-CoV-2 Gamma Variants and the Rapid Spread of P.1-like-II SARS-CoV-2 during the Second Wave of COVID-19 in Santa Catarina, Southern Brazil. <i>Viruses</i> , 2022, 14, 695.	1.5	8
255	E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces. <i>PeerJ</i> , 2022, 10, e13099.	0.9	3

#	ARTICLE	IF	CITATIONS
257	Generalized Methodology for the Quick Prediction of Variant SARS-CoV-2 Spike Protein Binding Affinities with Human Angiotensin-Converting Enzyme II. <i>Journal of Physical Chemistry B</i> , 2022, 126, 2353-2360.	1.2	7
259	In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. <i>Scientific Reports</i> , 2022, 12, 4683.	1.6	33
260	Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell entry process, and cytokine storm in COVID-19. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 964-986.	1.2	8
261	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
262	High Seroprevalence of SARS-CoV-2 in White-Tailed Deer (<i>Odocoileus virginianus</i>) at One of Three Captive Cervid Facilities in Texas. <i>Microbiology Spectrum</i> , 2022, 10, e0057622.	1.2	30
263	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
264	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. <i>IScience</i> , 2022, 25, 103939.	1.9	32
268	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
269	The Runaway Evolution of SARS-CoV-2 Leading to the Highly Evolved Delta Strain. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	14
270	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
271	Nanotechnology and COVID-19: quo vadis?. <i>Journal of Nanoparticle Research</i> , 2022, 24, 62.	0.8	6
272	Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay. <i>Microbiology Spectrum</i> , 2022, 10, e0217621.	1.2	9
273	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	2.0	4
274	Comparative Analysis of SARS-CoV-2 Variants of Concern, Including Omicron, Highlights Their Common and Distinctive Amino Acid Substitution Patterns, Especially at the Spike ORF. <i>Viruses</i> , 2022, 14, 707.	1.5	30
276	SARS-CoV-2 variants and vulnerability at the global level. <i>Journal of Medical Virology</i> , 2022, 94, 2986-3005.	2.5	79
278	Identifying vaccine escape sites via statistical comparisons of short-term molecular dynamics. <i>Biophysical Reports</i> , 2022, 2, 100056.	0.7	2
279	Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. <i>Nature Medicine</i> , 2022, 28, 1491-1500.	15.2	239
280	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22

#	ARTICLE	IF	CITATIONS
281	A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 114.	7.1	17
282	Molecular Dynamics and MM-PBSA Analysis of the SARS-CoV-2 Gamma Variant in Complex with the hACE-2 Receptor. <i>Molecules</i> , 2022, 27, 2370.	1.7	10
285	New variants of SARS-CoV-2, vaccine immune response and the Brazilian reality. <i>Exploration of Immunology</i> , 0, , 432-439.	1.7	0
287	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3
288	Genomic Epidemiology of SARS-CoV-2 Divulge B.1, B.1.36, and B.1.1.7 as the Most Dominant Lineages in First, Second, and Third Wave of SARS-CoV-2 Infections in Pakistan. <i>Microorganisms</i> , 2021, 9, 2609.	1.6	17
289	Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization. <i>Viruses</i> , 2021, 13, 2440.	1.5	8
290	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
291	Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, e705-e714.	2.9	10
293	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
295	Emergence of novel combinations of SARS-CoV-2 spike receptor binding domain variants in Senegal. <i>Scientific Reports</i> , 2021, 11, 23644.	1.6	4
296	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. <i>PLoS Biology</i> , 2021, 19, e3001384.	2.6	15
297	A multi-step and multi-scale bioinformatic approach to investigate potential source of cross-reactive immunity against SARS-CoV-2 UK variant. , 2021, , .		0
298	Assessing Differential Binding of Aggregation-Induced Emission-Based Luminogens to Host Interacting Surface Proteins of SARS-CoV-2 and Influenza Virus—An in silico Approach. <i>Frontiers in Microbiology</i> , 2021, 12, 766351.	1.5	2
300	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
301	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	1.6	12
302	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. <i>Science Translational Medicine</i> , 2022, 14, eabn1252.	5.8	68
303	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
304	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32

#	ARTICLE	IF	CITATIONS
305	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
307	SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination. <i>Viruses</i> , 2022, 14, 814.	1.5	2
308	Evaluation of phytoconstituents of <i>Tinospora cordifolia</i> against K417N and N501Y mutant spike glycoprotein and main protease of SARS-CoV-2- an in silico study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 4106-4123.	2.0	1
309	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
310	SARS-CoV-2: Evolution and Emergence of New Viral Variants. <i>Viruses</i> , 2022, 14, 653.	1.5	39
311	Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
312	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
313	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. <i>Viruses</i> , 2022, 14, 854.	1.5	5
314	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24
315	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. <i>Pathogens</i> , 2022, 11, 516.	1.2	10
316	Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 138.	7.1	140
317	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	2.9	287
318	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
319	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2210780.	2.8	27
320	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
321	T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
322	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
323	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	39

#	ARTICLE	IF	CITATIONS
324	Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1. <i>Science Immunology</i> , 2022, 7, eabo3425.	5.6	28
326	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
327	An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation. <i>Journal of Molecular Biology</i> , 2022, 434, 167637.	2.0	1
328	Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants. <i>Cell and Bioscience</i> , 2022, 12, 63.	2.1	4
329	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
331	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
332	Current molecular diagnostics assays for SARS-CoV-2 and emerging variants. <i>Methods in Microbiology</i> , 2022, , 83-121.	0.4	2
333	VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages. <i>Journal of Personalized Medicine</i> , 2022, 12, 895.	1.1	2
334	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
335	Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1207-1221.	1.2	3
336	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
337	Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104431.	1.9	3
338	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	149
339	Covid-19, an unfinished story. <i>Presse Medicale</i> , 2022, 51, 104131.	0.8	8
340	Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies. <i>Cell Discovery</i> , 2022, 8, .	3.1	40
341	Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 874.	2.1	5
342	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
343	Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents. <i>PLoS ONE</i> , 2022, 17, e0268806.	1.1	14

#	ARTICLE	IF	CITATIONS
344	Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3107-3122.	2.5	5
345	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. <i>International Journal of Translational Medicine</i> , 2022, 2, 275-308.	0.1	1
346	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
347	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	34
348	Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
349	Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant. <i>Clinics</i> , 2022, 77, 100068.	0.6	2
350	A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. <i>Future Virology</i> , 0, , .	0.9	4
351	Natural selection plays a significant role in governing the codon usage bias in the novel SARS-CoV-2 variants of concern (VOC). <i>PeerJ</i> , 0, 10, e13562.	0.9	4
353	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. <i>Nature Communications</i> , 2022, 13, .	5.8	22
354	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
356	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262.	1.7	9
357	Multiplex Quantitative Polymerase Chain Reaction Test to Identify SARS-CoV-2 Variants. <i>Methods in Molecular Biology</i> , 2022, , 67-78.	0.4	1
359	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
360	Introduction and Establishment of SARS-CoV-2 Gamma Variant in New York City in Early 2021. <i>Journal of Infectious Diseases</i> , 2022, 226, 2142-2149.	1.9	5
361	Tixagevimab and cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 972-984.	5.2	61
362	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675.	1.8	9
363	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	26
365	Detecting lineage-defining mutations in SARS-CoV-2 using colorimetric RT-LAMP without probes or additional primers. <i>Scientific Reports</i> , 2022, 12, .	1.6	4

#	ARTICLE	IF	CITATIONS
366	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
367	Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	3
368	Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
370	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. <i>EClinicalMedicine</i> , 2022, 50, 101529.	3.2	3
371	A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. <i>Antiviral Research</i> , 2022, 204, 105370.	1.9	16
372	Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study. <i>EClinicalMedicine</i> , 2022, 51, 101542.	3.2	5
373	Spread of endemic SARS-CoV-2 lineages in Russia before April 2021. <i>PLoS ONE</i> , 2022, 17, e0270717.	1.1	8
375	Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.	1.5	27
376	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
377	Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern. <i>Biology Methods and Protocols</i> , 2022, 7, .	1.0	1
378	Density functional theory computation of the binding free energies between various mutations of SARS-CoV-2 RBD and human ACE2: molecular level roots of the contagiousness. <i>Heliyon</i> , 2022, 8, e10128.	1.4	2
379	Effectiveness of Household Disinfection Techniques to Remove SARS-CoV-2 from Cloth Masks. <i>Pathogens</i> , 2022, 11, 916.	1.2	2
380	Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution. <i>Acta Crystallographica Section D: Structural Biology</i> , 2022, 78, 1156-1170.	1.1	2
381	A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. <i>ELife</i> , 0, 11, .	2.8	10
382	Molecular Dynamics Analysis of Fast-Spreading Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Their Effects on the Interaction with Human Angiotensin-Converting Enzyme 2. <i>ACS Omega</i> , 2022, 7, 30700-30709.	1.6	6
383	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
384	A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. <i>PLoS ONE</i> , 2022, 17, e0272364.	1.1	6
386	Two Years into the COVID-19 Pandemic: Lessons Learned. <i>ACS Infectious Diseases</i> , 2022, 8, 1758-1814.	1.8	47

#	ARTICLE	IF	CITATIONS
387	Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
388	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. <i>Nature Communications</i> , 2022, 13, .	5.8	12
389	Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. <i>Vaccines</i> , 2022, 10, 1251.	2.1	10
390	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COVS vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
391	Nanotechnology-based strategies against SARS-CoV-2 variants. <i>Nature Nanotechnology</i> , 2022, 17, 1027-1037.	15.6	63
392	Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern. <i>ESMO Open</i> , 2022, 7, 100574.	2.0	12
393	Structural aspects of SARS-CoV-2 mutations: Implications to plausible infectivity with ACE-2 using computational modeling approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6518-6533.	2.0	9
394	COVID-19 mRNA Vaccines. , 2022, , 769-802.		0
395	Will New Variants Emerge after Delta and Omicron?. , 2022, 13, 1317.		1
396	Titers and Capacity of Neutralizing Antibodies Against SARS-CoV-2 Variants after Heterologous Booster Vaccination in Health Care Workers Primed with Two Doses of ChadOx1 nCov-19: A Single-Blinded, Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
397	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
398	Low Seroprevalence of SARS-CoV-2 among Healthcare Workers in Malaysia during the Third COVID-19 Wave: Prospective Study with Literature Survey on Infection Prevention and Control Measures. <i>Healthcare (Switzerland)</i> , 2022, 10, 1810.	1.0	0
400	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
401	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
402	Computation of the Binding Energies between Human ACE2 and Spike RBDs of the Original Strain, Delta and Omicron Variants of the SARS-CoV-2: A DFT Simulation Approach. <i>Advanced Theory and Simulations</i> , 2022, 5, .	1.3	6
403	RNA G-quadruplex formed in SARS-CoV-2 used for COVID-19 treatment in animal models. <i>Cell Discovery</i> , 2022, 8, .	3.1	28
404	Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case. <i>European Biophysics Journal</i> , 2022, 51, 555-568.	1.2	4
405	Localized delivery of nanomedicine and antibodies for combating COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1828-1846.	5.7	5

#	ARTICLE	IF	CITATIONS
406	Safety and immunogenicity of intradermal administration of fractional dose CoronaVac [®] , ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
407	Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2023, 76, 201-209.	2.9	10
408	Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
409	Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SP. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
410	Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 2749-2761.	3.0	9
412	Homology Modeling and Molecular Dynamics-Driven Search for Natural Inhibitors That Universally Target Receptor-Binding Domain of Spike Glycoprotein in SARS-CoV-2 Variants. <i>Molecules</i> , 2022, 27, 7336.	1.7	1
413	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
414	Retrospective Analysis of the SARS-CoV-2 Infection Profile in COVID-19 Positive Patients in Vitoria da Conquista, Northeast Brazil. <i>Viruses</i> , 2022, 14, 2424.	1.5	3
415	Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review. <i>Expert Review of Anti-Infective Therapy</i> , 0, , 1-11.	2.0	3
416	Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of <sc>SARS-CoV</sc>. <i>Protein Science</i> , 2022, 31, .	3.1	1
417	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemo-Biological Interactions</i> , 2022, 368, 110244.	1.7	4
418	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	1.3	7
419	The Concomitant Use of Melatonin and Bebtelovimab as a Treatment Strategy for Omicron and Future Variants of Concern. <i>International Journal of Pharmaceutical Research and Allied Sciences</i> , 2022, 11, 33-40.	0.1	1
421	Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
423	Antibody multispecificity: A necessary evil?. <i>Molecular Immunology</i> , 2022, 152, 153-161.	1.0	4
424	Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial. <i>Journal of Clinical Virology</i> , 2022, 157, 105328.	1.6	10
425	Green and Regioselective Approach for the Synthesis of 3-Substituted Indole Based 1,2-Dihydropyridine and Azaxanthone Derivatives as a Potential Lead for SARS-CoV-2 and Delta Plus Mutant Virus: DFT and Docking Studies. <i>ACS Omega</i> , 0, , .	1.6	3
426	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. <i>PLoS ONE</i> , 2022, 17, e0277745.	1.1	4

#	ARTICLE	IF	CITATIONS
427	COVID-19 endgame: From pandemic to endemic? Vaccination, reopening and evolution in low- and high-vaccinated populations. <i>Journal of Theoretical Biology</i> , 2023, 559, 111368.	0.8	29
428	Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. <i>Molecules</i> , 2022, 27, 8257.	1.7	4
429	Modelling optimal lockdowns with waning immunity. <i>Economic Theory</i> , 2024, 77, 197-234.	0.5	7
430	Efficacy and Safety of COVID-19 Vaccines—An Update. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 112.	1.0	11
431	Comparative study of Wuhan-like and omicron-like variants of SARS-CoV-2 in experimental animal models. <i>Voprosy Virusologii</i> , 2022, 67, 439-449.	0.1	0
432	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
433	Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia. <i>Vaccines</i> , 2022, 10, 2144.	2.1	1
434	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
435	Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
436	A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. <i>Cell Reports</i> , 2023, 42, 111903.	2.9	34
437	SARS-CoV-2 Lineage P.4 Detection in Southeast Brazil: A Retrospective Genomic and Clinical Overview. <i>Covid</i> , 2022, 2, 1768-1777.	0.7	1
438	Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	1.4	2
439	Functionalized Fullerene for Inhibition of SARS-CoV-2 Variants. <i>Small</i> , 2023, 19, .	5.2	8
440	Rapid and Flexible RT-qPCR Surveillance Platforms To Detect SARS-CoV-2 Mutations. <i>Microbiology Spectrum</i> , 0, , .	1.2	4
441	Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. <i>Heliyon</i> , 2023, 9, e12704.	1.4	2
443	Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis. <i>Biotechnology Advances</i> , 2023, 65, 108143.	6.0	4
444	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3255.	1.8	4
445	Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19. <i>Npj Vaccines</i> , 2023, 8, .	2.9	2

#	ARTICLE	IF	CITATIONS
446	Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants. <i>Nature Communications</i> , 2023, 14, .	5.8	6
448	HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. <i>Vaccines</i> , 2023, 11, 548.	2.1	1
449	Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. <i>Cell Reports</i> , 2023, 42, 112271.	2.9	12
450	Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
451	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
453	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15207-15218.	2.0	1
454	In silico identification and molecular dynamic simulations of derivatives of 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide against main protease 3CLpro of SARS-CoV-2 viral infection. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	6
455	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
456	Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence. <i>Cell Reports</i> , 2023, 42, 112421.	2.9	3
457	Next-Generation Vaccines against COVID-19 Variants: Beyond the Spike Protein. <i>Zoonoses</i> , 2023, 3, .	0.5	1
458	COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	2
471	The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 3-26.	0.8	0
483	Chronicle the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
489	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
511	Innovation-driven trend shaping COVID-19 vaccine development in China. <i>Frontiers of Medicine</i> , 2023, 17, 1096-1116.	1.5	0